Anti-PD-1 and Anti-EGFR Antibody Combination for Refractory HNSCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that have failed first-line platinum-based therapy are limited in efficacy, with response rates below 10% and overall survival of 6-7 months, necessitating the development of more effective therapeutic strategies.
Innovation Solution
A combination of anti-PD-1 and anti-EGFR antibodies or their antigen-binding fragments, specifically toripalimab and cetuximab, is administered to patients with PD-L1 expression ≥1%, targeting PD-1 and EGFR to enhance T cell activation and inhibit tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent chemotherapy is used for recurrent or metastatic HNSCC, then treatment simplicity is maintained, but response rate is lower than 10% and overall survival is only 6-7 months
Solution Approach 1:
The patent combines anti-PD-1 antibody (toripalimab) and anti-EGFR antibody (cetuximab) into a combination therapy regimen, merging two different mechanisms of action (immune checkpoint inhibition and EGFR signaling blockade) to achieve synergistic anti-tumor effects, thereby improving response rate and overall survival compared to single-agent chemotherapy
2Reliability
If nivolumab is used for patients with PD-L1≥1%, then immune checkpoint blockade effect is achieved, but it is not applicable to patients who have not been screened for biomarkers
Solution Approach 1:
The combination therapy serves multiple functions: it provides immune checkpoint blockade for PD-L1 positive patients while simultaneously offering EGFR pathway inhibition for all patients including those without biomarker screening. This dual mechanism makes the treatment universally applicable regardless of PD-L1 status, expanding adaptability to unscreened patient populations
3Reliability
If combination of anti-PD-1 and anti-EGFR antibodies is administered, then T cell activation is enhanced and tumor growth is inhibited, but treatment complexity increases
Solution Approach 1:
The treatment protocol is segmented into distinct administration schedules with clear timing specifications (toripalimab every 2 or 3 weeks, cetuximab weekly or every 2 weeks). This segmentation of dosing schedules simplifies the management of combination therapy by providing structured, manageable intervals for each agent, reducing the perceived complexity despite the dual-mechanism approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly improves survival and reduces tumor burden in patients with recurrent or metastatic HNSCC, offering a therapeutic benefit beyond existing monotherapies.
Implementation Method 1
The binding of PD-1/PD-L1 plays an important role in down-regulating T cell activation and maintaining peripheral immune tolerance. Therefore, tumor cells express PD-L1, which further interacts with PD-1 to inhibit T cell activation, allowing the tumor cells to escape from killing by immune cells. By blocking such immune checkpoints, the proliferation, survival, and killing activity of T cells can be enhanced
Implementation Method 2
Monoclonal antibodies targeting EGFR can block the binding of EGF and other ligands to EGFR, preventing dimerization of EGFR and thus inhibiting ligand-induced activation of this receptor tyrosine kinase. This leads to the inhibition of cell growth, the induction of cell apoptosis, and the reduction in the synthesis of matrix metalloproteinases and vascular endothelial growth factors
Implementation Method 3
In addition, monoclonal antibodies targeting EGFR can mediate antibody-dependent, cell-mediated cytotoxicity: this process depends on both the affinity of the monoclonal antibodies for the extracellular domain of EGFR and the expression level of cellular EGFR
Data Source
AI summary
Provided are a combination of an anti-PD-1 antibody and an anti-EGFR antibody and the use thereof in the treatment of head and neck squamous cell carcinoma. Specifically, provided is a drug combination comprising an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof. The drug combination exhibits good curative effect in the treatment of head and neck squamous cell carcinoma.